These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 29775538)

  • 1. Discovery of Potent and Centrally Active 6-Substituted 5-Fluoro-1,3-dihydro-oxazine β-Secretase (BACE1) Inhibitors via Active Conformation Stabilization.
    Nakahara K; Fuchino K; Komano K; Asada N; Tadano G; Hasegawa T; Yamamoto T; Sako Y; Ogawa M; Unemura C; Hosono M; Ito H; Sakaguchi G; Ando S; Ohnishi S; Kido Y; Fukushima T; Dhuyvetter D; Borghys H; Gijsen HJM; Yamano Y; Iso Y; Kusakabe KI
    J Med Chem; 2018 Jul; 61(13):5525-5546. PubMed ID: 29775538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rational Design of Novel 1,3-Oxazine Based β-Secretase (BACE1) Inhibitors: Incorporation of a Double Bond To Reduce P-gp Efflux Leading to Robust Aβ Reduction in the Brain.
    Fuchino K; Mitsuoka Y; Masui M; Kurose N; Yoshida S; Komano K; Yamamoto T; Ogawa M; Unemura C; Hosono M; Ito H; Sakaguchi G; Ando S; Ohnishi S; Kido Y; Fukushima T; Miyajima H; Hiroyama S; Koyabu K; Dhuyvetter D; Borghys H; Gijsen HJM; Yamano Y; Iso Y; Kusakabe KI
    J Med Chem; 2018 Jun; 61(12):5122-5137. PubMed ID: 29733614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Umibecestat (CNP520): A Potent, Selective, and Efficacious β-Secretase (BACE1) Inhibitor for the Prevention of Alzheimer's Disease.
    Machauer R; Lueoend R; Hurth K; Veenstra SJ; Rueeger H; Voegtle M; Tintelnot-Blomley M; Rondeau JM; Jacobson LH; Laue G; Beltz K; Neumann U
    J Med Chem; 2021 Oct; 64(20):15262-15279. PubMed ID: 34648711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trifluoromethyl Dihydrothiazine-Based β-Secretase (BACE1) Inhibitors with Robust Central β-Amyloid Reduction and Minimal Covalent Binding Burden.
    Anan K; Iso Y; Oguma T; Nakahara K; Suzuki S; Yamamoto T; Matsuoka E; Ito H; Sakaguchi G; Ando S; Morimoto K; Kanegawa N; Kido Y; Kawachi T; Fukushima T; Teisman A; Urmaliya V; Dhuyvetter D; Borghys H; Austin N; Van Den Bergh A; Verboven P; Bischoff F; Gijsen HJM; Yamano Y; Kusakabe K
    ChemMedChem; 2019 Nov; 14(22):1894-1910. PubMed ID: 31657130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of amino-1,4-oxazines as potent BACE-1 inhibitors.
    Veenstra SJ; Rueeger H; Voegtle M; Lueoend R; Holzer P; Hurth K; Tintelnot-Blomley M; Frederiksen M; Rondeau JM; Jacobson L; Staufenbiel M; Neumann U; Machauer R
    Bioorg Med Chem Lett; 2018 Jul; 28(12):2195-2200. PubMed ID: 29764741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1,4-Oxazine β-Secretase 1 (BACE1) Inhibitors: From Hit Generation to Orally Bioavailable Brain Penetrant Leads.
    Rombouts FJ; Tresadern G; Delgado O; Martínez-Lamenca C; Van Gool M; García-Molina A; Alonso de Diego SA; Oehlrich D; Prokopcova H; Alonso JM; Austin N; Borghys H; Van Brandt S; Surkyn M; De Cleyn M; Vos A; Alexander R; Macdonald G; Moechars D; Gijsen H; Trabanco AA
    J Med Chem; 2015 Oct; 58(20):8216-35. PubMed ID: 26378740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis of the Potent, Selective, and Efficacious β-Secretase (BACE1) Inhibitor NB-360.
    Rueeger H; Lueoend R; Machauer R; Veenstra SJ; Holzer P; Hurth K; Voegtle M; Frederiksen M; Rondeau JM; Tintelnot-Blomley M; Jacobson LH; Staufenbiel M; Laue G; Neumann U
    J Med Chem; 2021 Apr; 64(8):4677-4696. PubMed ID: 33844524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-Based Approaches to Improving Selectivity through Utilizing Explicit Water Molecules: Discovery of Selective β-Secretase (BACE1) Inhibitors over BACE2.
    Fujimoto K; Yoshida S; Tadano G; Asada N; Fuchino K; Suzuki S; Matsuoka E; Yamamoto T; Yamamoto S; Ando S; Kanegawa N; Tonomura Y; Ito H; Moechars D; Rombouts FJR; Gijsen HJM; Kusakabe KI
    J Med Chem; 2021 Mar; 64(6):3075-3085. PubMed ID: 33719429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishing the relationship between in vitro potency, pharmacokinetic, and pharmacodynamic parameters in a series of orally available, hydroxyethylamine-derived β-secretase inhibitors.
    Wood S; Wen PH; Zhang J; Zhu L; Luo Y; Babu-Khan S; Chen K; Pham R; Esmay J; Dineen TA; Kaller MR; Weiss MM; Hitchcock SA; Citron M; Zhong W; Hickman D; Williamson T
    J Pharmacol Exp Ther; 2012 Nov; 343(2):460-7. PubMed ID: 22911925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of 1,4-Oxazine β-Secretase 1 (BACE1) Inhibitors Toward a Clinical Candidate.
    Gijsen HJM; Alonso de Diego SA; De Cleyn M; García-Molina A; Macdonald GJ; Martínez-Lamenca C; Oehlrich D; Prokopcova H; Rombouts FJR; Surkyn M; Trabanco AA; Van Brandt S; Van den Bossche D; Van Gool M; Austin N; Borghys H; Dhuyvetter D; Moechars D
    J Med Chem; 2018 Jun; 61(12):5292-5303. PubMed ID: 29809004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. β-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's disease.
    Hilpert H; Guba W; Woltering TJ; Wostl W; Pinard E; Mauser H; Mayweg AV; Rogers-Evans M; Humm R; Krummenacher D; Muser T; Schnider C; Jacobsen H; Ozmen L; Bergadano A; Banner DW; Hochstrasser R; Kuglstatter A; David-Pierson P; Fischer H; Polara A; Narquizian R
    J Med Chem; 2013 May; 56(10):3980-95. PubMed ID: 23590342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.
    Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF
    J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From fragment screening to in vivo efficacy: optimization of a series of 2-aminoquinolines as potent inhibitors of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1).
    Cheng Y; Judd TC; Bartberger MD; Brown J; Chen K; Fremeau RT; Hickman D; Hitchcock SA; Jordan B; Li V; Lopez P; Louie SW; Luo Y; Michelsen K; Nixey T; Powers TS; Rattan C; Sickmier EA; St Jean DJ; Wahl RC; Wen PH; Wood S
    J Med Chem; 2011 Aug; 54(16):5836-57. PubMed ID: 21707077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decrease in the Generation of Amyloid-β Due to Salvianolic Acid B by Modulating BACE1 Activity.
    Durairajan SSK; Chirasani VR; Shetty SG; Iyaswamy A; Malampati S; Song J; Liu L; Huang J; Senapati S; Li M
    Curr Alzheimer Res; 2017; 14(11):1229-1237. PubMed ID: 28413985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of S3-Truncated, C-6 Heteroaryl Substituted Aminothiazine β-Site APP Cleaving Enzyme-1 (BACE1) Inhibitors.
    Wu YJ; Guernon J; Shi J; Marcin L; Higgins M; Rajamani R; Muckelbauer J; Lewis H; Chang C; Camac D; Toyn JH; Ahlijanian MK; Albright CF; Macor JE; Thompson LA
    J Med Chem; 2016 Sep; 59(18):8593-600. PubMed ID: 27559936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diastereoselective synthesis of fused cyclopropyl-3-amino-2,4-oxazine β-amyloid cleaving enzyme (BACE) inhibitors and their biological evaluation.
    Low JD; Bartberger MD; Cheng Y; Whittington D; Xue Q; Wood S; Allen JR; Minatti AE
    Bioorg Med Chem Lett; 2018 Apr; 28(6):1111-1115. PubMed ID: 29426770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of BACE1 inhibitors from Panax ginseng saponins-An Insilco approach.
    Karpagam V; Sathishkumar N; Sathiyamoorthy S; Rasappan P; Shila S; Kim YJ; Yang DC
    Comput Biol Med; 2013 Sep; 43(8):1037-44. PubMed ID: 23816176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymethoxyflavones: Novel β-Secretase (BACE1) Inhibitors from Citrus Peels.
    Youn K; Yu Y; Lee J; Jeong WS; Ho CT; Jun M
    Nutrients; 2017 Sep; 9(9):. PubMed ID: 28869548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a series of efficient, centrally efficacious BACE1 inhibitors through structure-based drug design.
    Butler CR; Brodney MA; Beck EM; Barreiro G; Nolan CE; Pan F; Vajdos F; Parris K; Varghese AH; Helal CJ; Lira R; Doran SD; Riddell DR; Buzon LM; Dutra JK; Martinez-Alsina LA; Ogilvie K; Murray JC; Young JM; Atchison K; Robshaw A; Gonzales C; Wang J; Zhang Y; O'Neill BT
    J Med Chem; 2015 Mar; 58(6):2678-702. PubMed ID: 25695670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Revisiting the peripheral sink hypothesis: inhibiting BACE1 activity in the periphery does not alter β-amyloid levels in the CNS.
    Georgievska B; Gustavsson S; Lundkvist J; Neelissen J; Eketjäll S; Ramberg V; Bueters T; Agerman K; Juréus A; Svensson S; Berg S; Fälting J; Lendahl U
    J Neurochem; 2015 Feb; 132(4):477-86. PubMed ID: 25156639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.